Selected research
Industry Research
Trastuzumab Biosimilar Industry Research Report 2026
Market perspective
The global Trastuzumab Biosimilar market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Trastuzumab Biosimilar is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Trastuzumab Biosimilar is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Trastuzumab Biosimilar is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Trastuzumab Biosimilar include Mundipharma, Samsung Bioepis, Amgen Inc., Biocon Limited, Henlius, Pfizer Inc, Genentech, Merck & Co. and Celltrion, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Trastuzumab Biosimilar market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Trastuzumab Biosimilar Market by Company
Mundipharma
Samsung Bioepis
Amgen Inc.
Biocon Limited
Henlius
Pfizer Inc
Genentech
Merck & Co.
Celltrion
Teva Pharmaceutical
Trastuzumab Biosimilar Segment by Type
Adjuvant Breast Cancer
Metastatic Breast Cancer
Metastatic Gastric Cancer
Others
Trastuzumab Biosimilar Segment by Application
Hospital Pharmacy
Online Pharmacy
Trastuzumab Biosimilar Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Trastuzumab Biosimilar market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Trastuzumab Biosimilar and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Trastuzumab Biosimilar.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Trastuzumab Biosimilar manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Trastuzumab Biosimilar by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Trastuzumab Biosimilar in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Adjuvant Breast Cancer
- Metastatic Breast Cancer
- Metastatic Gastric Cancer
- Others
Applications
- Hospital Pharmacy
- Online Pharmacy
Companies covered
- Mundipharma
- Samsung Bioepis
- Amgen Inc.
- Biocon Limited
- Henlius
- Pfizer Inc
- Genentech
- Merck & Co.
- Celltrion
- Teva Pharmaceutical
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Trastuzumab Biosimilar Market Size (2021-2032)
- 2.2.2 Global Trastuzumab Biosimilar Sales (2021-2032)
- 2.2.3 Global Trastuzumab Biosimilar Market Average Price (2021-2032)
- 2.3 Trastuzumab Biosimilar by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Adjuvant Breast Cancer
- 2.3.3 Metastatic Breast Cancer
- 2.3.4 Metastatic Gastric Cancer
- 2.3.5 Others
- 2.4 Trastuzumab Biosimilar by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital Pharmacy
- 2.4.3 Online Pharmacy
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Trastuzumab Biosimilar Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Trastuzumab Biosimilar Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Trastuzumab Biosimilar Revenue of Manufacturers (2021-2026)
- 3.4 Global Trastuzumab Biosimilar Average Price by Manufacturers (2021-2026)
- 3.5 Global Trastuzumab Biosimilar Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Trastuzumab Biosimilar, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Trastuzumab Biosimilar, Product Type & Application
- 3.8 Global Manufacturers of Trastuzumab Biosimilar, Established Date
- 3.9 Global Trastuzumab Biosimilar Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Mundipharma
- 4.1.1 Mundipharma Company Information
- 4.1.2 Mundipharma Business Overview
- 4.1.3 Mundipharma Trastuzumab Biosimilar Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Mundipharma Trastuzumab Biosimilar Product Portfolio
- 4.1.5 Mundipharma Recent Developments
- 4.2 Samsung Bioepis
- 4.2.1 Samsung Bioepis Company Information
- 4.2.2 Samsung Bioepis Business Overview
- 4.2.3 Samsung Bioepis Trastuzumab Biosimilar Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Samsung Bioepis Trastuzumab Biosimilar Product Portfolio
- 4.2.5 Samsung Bioepis Recent Developments
- 4.3 Amgen Inc.
- 4.3.1 Amgen Inc. Company Information
- 4.3.2 Amgen Inc. Business Overview
- 4.3.3 Amgen Inc. Trastuzumab Biosimilar Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Amgen Inc. Trastuzumab Biosimilar Product Portfolio
- 4.3.5 Amgen Inc. Recent Developments
- 4.4 Biocon Limited
- 4.4.1 Biocon Limited Company Information
- 4.4.2 Biocon Limited Business Overview
- 4.4.3 Biocon Limited Trastuzumab Biosimilar Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Biocon Limited Trastuzumab Biosimilar Product Portfolio
- 4.4.5 Biocon Limited Recent Developments
- 4.5 Henlius
- 4.5.1 Henlius Company Information
- 4.5.2 Henlius Business Overview
- 4.5.3 Henlius Trastuzumab Biosimilar Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Henlius Trastuzumab Biosimilar Product Portfolio
- 4.5.5 Henlius Recent Developments
- 4.6 Pfizer Inc
- 4.6.1 Pfizer Inc Company Information
- 4.6.2 Pfizer Inc Business Overview
- 4.6.3 Pfizer Inc Trastuzumab Biosimilar Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Pfizer Inc Trastuzumab Biosimilar Product Portfolio
- 4.6.5 Pfizer Inc Recent Developments
- 4.7 Genentech
- 4.7.1 Genentech Company Information
- 4.7.2 Genentech Business Overview
- 4.7.3 Genentech Trastuzumab Biosimilar Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Genentech Trastuzumab Biosimilar Product Portfolio
- 4.7.5 Genentech Recent Developments
- 4.8 Merck & Co.
- 4.8.1 Merck & Co. Company Information
- 4.8.2 Merck & Co. Business Overview
- 4.8.3 Merck & Co. Trastuzumab Biosimilar Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Merck & Co. Trastuzumab Biosimilar Product Portfolio
- 4.8.5 Merck & Co. Recent Developments
- 4.9 Celltrion
- 4.9.1 Celltrion Company Information
- 4.9.2 Celltrion Business Overview
- 4.9.3 Celltrion Trastuzumab Biosimilar Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Celltrion Trastuzumab Biosimilar Product Portfolio
- 4.9.5 Celltrion Recent Developments
- 4.10 Teva Pharmaceutical
- 4.10.1 Teva Pharmaceutical Company Information
- 4.10.2 Teva Pharmaceutical Business Overview
- 4.10.3 Teva Pharmaceutical Trastuzumab Biosimilar Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Teva Pharmaceutical Trastuzumab Biosimilar Product Portfolio
- 4.10.5 Teva Pharmaceutical Recent Developments
5 Global Trastuzumab Biosimilar Market Scenario by Region
- 5.1 Global Trastuzumab Biosimilar Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Trastuzumab Biosimilar Sales by Region: 2021-2032
- 5.2.1 Global Trastuzumab Biosimilar Sales by Region: 2021-2026
- 5.2.2 Global Trastuzumab Biosimilar Sales by Region: 2027-2032
- 5.3 Global Trastuzumab Biosimilar Revenue by Region: 2021-2032
- 5.3.1 Global Trastuzumab Biosimilar Revenue by Region: 2021-2026
- 5.3.2 Global Trastuzumab Biosimilar Revenue by Region: 2027-2032
- 5.4 North America Trastuzumab Biosimilar Market Facts & Figures by Country
- 5.4.1 North America Trastuzumab Biosimilar Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Trastuzumab Biosimilar Sales by Country (2021-2032)
- 5.4.3 North America Trastuzumab Biosimilar Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Trastuzumab Biosimilar Market Facts & Figures by Country
- 5.5.1 Europe Trastuzumab Biosimilar Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Trastuzumab Biosimilar Sales by Country (2021-2032)
- 5.5.3 Europe Trastuzumab Biosimilar Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Trastuzumab Biosimilar Market Facts & Figures by Country
- 5.6.1 Asia Pacific Trastuzumab Biosimilar Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Trastuzumab Biosimilar Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Trastuzumab Biosimilar Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Trastuzumab Biosimilar Market Facts & Figures by Country
- 5.7.1 South America Trastuzumab Biosimilar Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Trastuzumab Biosimilar Sales by Country (2021-2032)
- 5.7.3 South America Trastuzumab Biosimilar Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Trastuzumab Biosimilar Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Trastuzumab Biosimilar Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Trastuzumab Biosimilar Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Trastuzumab Biosimilar Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Trastuzumab Biosimilar Sales by Type (2021-2032)
- 6.1.1 Global Trastuzumab Biosimilar Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Trastuzumab Biosimilar Sales Market Share by Type (2021-2032)
- 6.2 Global Trastuzumab Biosimilar Revenue by Type (2021-2032)
- 6.2.1 Global Trastuzumab Biosimilar Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Trastuzumab Biosimilar Revenue Market Share by Type (2021-2032)
- 6.3 Global Trastuzumab Biosimilar Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Trastuzumab Biosimilar Sales by Application (2021-2032)
- 7.1.1 Global Trastuzumab Biosimilar Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Trastuzumab Biosimilar Sales Market Share by Application (2021-2032)
- 7.2 Global Trastuzumab Biosimilar Revenue by Application (2021-2032)
- 7.2.1 Global Trastuzumab Biosimilar Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Trastuzumab Biosimilar Revenue Market Share by Application (2021-2032)
- 7.3 Global Trastuzumab Biosimilar Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Trastuzumab Biosimilar Value Chain Analysis
- 8.1.1 Trastuzumab Biosimilar Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Trastuzumab Biosimilar Production Mode & Process
- 8.2 Trastuzumab Biosimilar Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Trastuzumab Biosimilar Distributors
- 8.2.3 Trastuzumab Biosimilar Customers
9 Global Trastuzumab Biosimilar Analyzing Market Dynamics
- 9.1 Trastuzumab Biosimilar Industry Trends
- 9.2 Trastuzumab Biosimilar Industry Drivers
- 9.3 Trastuzumab Biosimilar Industry Opportunities and Challenges
- 9.4 Trastuzumab Biosimilar Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst